Statins hold open a muscle calcium channel, explaining why some patients get muscle pain
Cryo-EM shows atorvastatin locks open the RyR1 calcium channel in muscle cells, a likely cause of statin muscle pain and a roadmap for safer drugs.
Summary
Statins are among the most widely used drugs for preventing heart attacks and strokes, yet some people develop muscle pain or weakness, and a few suffer severe muscle breakdown. Researchers at the University of British Columbia and the University of Wisconsin-Madison used cryo-electron microscopy to see how atorvastatin interacts with RyR1, a protein that acts as a calcium gateway in muscle cells. They found that three statin molecules settle into one pocket on the channel. The first binds while the channel is closed and makes it more likely to open. Two more then enter and hold it open, so calcium leaks continuously and can injure muscle tissue. The findings, published in Nature Communications, give drug developers a structural roadmap for redesigning statins that keep their cholesterol-lowering power without touching muscle. Because muscle strength matters for healthy aging, this work speaks directly to keeping people on heart-protective therapy while preserving function.
Detailed Summary
Statins are a cornerstone of cardiovascular prevention, lowering cholesterol and reducing the risk of heart attack and stroke in millions of people. Yet muscle symptoms, ranging from aches and weakness to rare, severe muscle breakdown that can lead to kidney failure, cause many patients to cut back or stop treatment. For anyone focused on aging well, this matters twice over: cardiovascular protection and preserved muscle function are both central to healthspan.
Researchers at the University of British Columbia, working with the University of Wisconsin-Madison, used cryo-electron microscopy to visualize how atorvastatin interacts with the ryanodine receptor (RyR1). This protein normally works as a tightly controlled gate, releasing calcium inside muscle cells only when a contraction is needed. The team found that statins can bind the channel and hold it open, producing a continuous calcium leak that can injure muscle tissue.
The binding pattern was unusual. Three statin molecules occupy a single pocket in the protein. The first attaches while the channel is closed and makes opening more likely. Two more then enter and keep it open. Lead author Steven Molinarolo said the team could see, almost atom by atom, how statins latch on. Senior author Filip Van Petegem described it as a roadmap for designing statins that do not interact with muscle.
The practical implication is for drug development: modifying the features of the statin molecule that engage RyR1 could preserve the cholesterol-lowering effect while sparing muscle. For now nothing changes for patients. Statins remain highly effective, and anyone with muscle symptoms should talk with a clinician about dose adjustment or alternatives rather than stopping on their own.
Several caveats apply. The work centered on atorvastatin, and other statins may behave similarly but this has not been shown. It is a structural, mechanistic study, so it does not yet quantify how much this leak drives symptoms in real patients, and other mechanisms may contribute. Safer statins remain a future prospect that will need design, testing and clinical trials.
Key Findings
- Cryo-EM showed atorvastatin binds the muscle calcium channel RyR1 and holds it open, causing a continuous calcium leak.
- Three statin molecules share one pocket: the first promotes opening, and two more lock the channel open.
- The calcium leak offers a mechanism for statin muscle pain, weakness, and severe muscle breakdown in rare cases.
- Other statins may act similarly, but atorvastatin was the main focus of the study.
- The structure gives a roadmap for designing statins that keep cholesterol-lowering benefits while sparing muscle.
Methodology
This is a news summary of a peer-reviewed structural biology study published in Nature Communications, released by the University of British Columbia. The evidence is molecular imaging by cryo-electron microscopy, which is high-resolution but not a clinical outcomes study.
Study Limitations
The study focused on atorvastatin, and effects of other statins are inferred rather than shown. Structural data do not establish how much the calcium leak accounts for symptoms in patients, or at what doses. Check the Nature Communications paper for methods, concentrations tested, and any functional muscle data.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: